08
OCT
2026
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production
Comments : Off
BETHESDA, Md., October 8, 2026 — Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, and the UK National Health Service Blood and Transplant (“NHSBT”) announce that they have entered into a collaboration, as the culmination of months of joint efforts by the parties, to support production of the Company’s... Read More




